Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Arellano

Showing results (81-90 of 113) with videos related to

Pageof 12
Sort By:
Cancer Cell|November 17, 2012
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growthTaro Hitosugi, Lu Zhou, Shannon Elf, et al.
Molecular Cell|July 22, 2014
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growthChangliang Shan, Shannon Elf, Quanjiang Ji, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Nature Cell Biology|October 20, 2015
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signallingRuiting Lin, Shannon Elf, Changliang Shan, et al.
Blood Advances|February 3, 2026
Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML ReportJoshua F Zeidner, Jayanshu Jain, Rina Li Welkie, et al.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood|May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyMartha L Arellano, Michael J Thirman, John F DiPersio, et al.
Cancer|April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H Duong, Amy S Ruppert, Alice S Mims, et al.
Blood Advances|March 14, 2020
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemiaCatherine J Lee, Soyoung Kim, Heather R Tecca, et al.
Blood Advances|October 31, 2022
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlatesAntoine N Saliba, Scott H Kaufmann, Eytan M Stein, et al.
Pageof 12

Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Cancer Cell|November 17, 2012
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growthTaro Hitosugi, Lu Zhou, Shannon Elf, et al.
Molecular Cell|July 22, 2014
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growthChangliang Shan, Shannon Elf, Quanjiang Ji, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Nature Cell Biology|October 20, 2015
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signallingRuiting Lin, Shannon Elf, Changliang Shan, et al.
Blood Advances|February 3, 2026
Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML ReportJoshua F Zeidner, Jayanshu Jain, Rina Li Welkie, et al.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood|May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyMartha L Arellano, Michael J Thirman, John F DiPersio, et al.
Cancer|April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H Duong, Amy S Ruppert, Alice S Mims, et al.
Blood Advances|March 14, 2020
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemiaCatherine J Lee, Soyoung Kim, Heather R Tecca, et al.
Blood Advances|October 31, 2022
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlatesAntoine N Saliba, Scott H Kaufmann, Eytan M Stein, et al.
Pageof 12